Lineage Cell Therapeutics Inc
TASE:LCTX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.333
508.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LCTX stock under the Base Case scenario is 158.29 ILS. Compared to the current market price of 227.9 ILS, Lineage Cell Therapeutics Inc is Overvalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lineage Cell Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LCTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Lineage Cell Therapeutics Inc
Balance Sheet Decomposition
Lineage Cell Therapeutics Inc
Current Assets | 40.4m |
Cash & Short-Term Investments | 38.5m |
Receivables | 235k |
Other Current Assets | 1.7m |
Non-Current Assets | 62.4m |
PP&E | 4.6m |
Intangibles | 57.2m |
Other Non-Current Assets | 598k |
Current Liabilities | 15.3m |
Accounts Payable | 2.4m |
Accrued Liabilities | 3.7m |
Other Current Liabilities | 9.2m |
Non-Current Liabilities | 19.2m |
Long-Term Debt | 68k |
Other Non-Current Liabilities | 19.2m |
Earnings Waterfall
Lineage Cell Therapeutics Inc
Revenue
|
6.2m
USD
|
Cost of Revenue
|
-568k
USD
|
Gross Profit
|
5.6m
USD
|
Operating Expenses
|
-31.2m
USD
|
Operating Income
|
-25.6m
USD
|
Other Expenses
|
1.4m
USD
|
Net Income
|
-24.2m
USD
|
Free Cash Flow Analysis
Lineage Cell Therapeutics Inc
USD | |
Free Cash Flow | USD |
LCTX Profitability Score
Profitability Due Diligence
Lineage Cell Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Lineage Cell Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
LCTX Solvency Score
Solvency Due Diligence
Lineage Cell Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Lineage Cell Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LCTX Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for LCTX is 1 786.94 ILS with a low forecast of 1 415.54 ILS and a high forecast of 2 575.29 ILS.
Dividends
Current shareholder yield for LCTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LCTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one LCTX stock under the Base Case scenario is 158.29 ILS.
Compared to the current market price of 227.9 ILS, Lineage Cell Therapeutics Inc is Overvalued by 31%.